.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Dow
Accenture
Cantor Fitzgerald
Cerilliant
Argus Health
Deloitte
Baxter
Daiichi Sankyo
Fuji

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020405

« Back to Dashboard

NDA 020405 describes LANOXIN, which is a drug marketed by Covis Pharma Bv and Concordia Pharms Inc and is included in two NDAs. It is available from twelve suppliers. Additional details are available on the LANOXIN profile page.

The generic ingredient in LANOXIN is digoxin. There are ten drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the digoxin profile page.

Summary for 020405

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 020405

Ingredient-typeCardiac Glycosides

Medical Subject Heading (MeSH) Categories for 020405

Suppliers and Packaging for NDA: 020405

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LANOXIN digoxin TABLET;ORAL 020405 NDA AUTHORIZED GENERIC NCS HealthCare of KY, Inc dba Vangard Labs 0615-7935 0615-7935-39 30 TABLET in 1 BLISTER PACK (0615-7935-39)
LANOXIN digoxin TABLET;ORAL 020405 NDA AUTHORIZED GENERIC NCS HealthCare of KY, Inc dba Vangard Labs 0615-7935 0615-7935-30 6 BLISTER PACK in 1 BOX, UNIT-DOSE (0615-7935-30) > 5 TABLET in 1 BLISTER PACK

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength0.0625MG
Approval Date:Sep 30, 1997TE:RLD:Yes

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength0.125MG
Approval Date:Sep 30, 1997TE:ABRLD:Yes

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength0.1875MG
Approval Date:Sep 30, 1997TE:RLD:Yes


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Cipla
US Army
AstraZeneca
Dow
Teva
Citi
Farmers Insurance
Cantor Fitzgerald
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot